Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell symbols : Igms save search
IGM Biosciences Presents Data from T cell Engager Portfolio for Hematologic Malignancies at 2022 American Society of Hematology Annual Meeting
Published: 2022-12-11 (Crawled : 16:20) - globenewswire.com
SNYNF | News | $92.7 1.4K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $45.445 -1.44% 2.6M
|
Health Technology
| Email alert
Add to watchlist
IGMS | News | $7.69 -5.41% 120K
|
Health Technology
| Email alert
Add to watchlist
meeting
A Phase 1 Dose Escalation Study of IGM-2323, a Novel Anti-CD20 x Anti-CD3 IgM T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies
Published: 2021-12-11 (Crawled : 00:20) - igmbio.com
IGMS | News | $7.69 -5.41% 120K
|
Health Technology
| Email alert
Add to watchlist
igm-2323 anti-cd3 phase 1 t-cell
IGM Biosciences Presents Clinical Data from IGM-2323 in Patients with Advanced B Cell Malignancies at 2021 American Society of Hematology Annual Meeting
Published: 2021-12-11 (Crawled : 20:20) - globenewswire.com
IGMS | News | $7.69 -5.41% 120K
|
Health Technology
| Email alert
Add to watchlist
igm-2323 ema bioscience t-cell
SITC Poster: IGM-7354 is an anti-PD-L1 IgM antibody and IL-15 cytokine fusion that enhances NK and CD8+ T cell proliferation and tumor cytotoxicity plus potently reverses T cell exhaustion
Published: 2021-11-12 (Crawled : 13:00) - igmbio.com
IGMS | News | $7.69 -5.41% 120K
|
Health Technology
|
| O: 0.66%
H: 0.0%
C: 0.0%
antibody t-cell
SITC Abstract: IGM-7354 is an anti-PD-L1 IgM antibody and IL-15 cytokine fusion that enhances NK and CD8+ T cell proliferation and tumor cytotoxicity plus potently reverses T cell exhaustion
Published: 2021-11-09 (Crawled : 13:15) - igmbio.com
IGMS | News | $7.69 -5.41% 120K
|
Health Technology
|
| O: -4.19%
H: 0.0%
C: 0.0%
antibody t-cell
Abstract #132: A Phase 1 Dose Escalation Study of IGM-2323, a Novel Anti-CD20 x Anti-CD3 IgM T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies
Published: 2021-11-04 (Crawled : 14:00) - igmbio.com
IGMS | News | $7.69 -5.41% 120K
|
Health Technology
|
| O: -9.65%
H: 10.43%
C: 8.35%
anti-cd3 phase 1 t-cell
Gainers vs Losers
| 80% | 20% |
Top 10 Gainers
AGBA | $0.7995 99.88% 73M
|
Finance
BPTH | $6.21 91.67% 58M
|
Health Technology
INVO | $1.36 78.95% 3.6M
|
Health Technology
TIRX | $0.8231 69.78% 54M
|
ISPC | $0.307 44.13% 3.6M
|
Professional, Scientific, and T...
SINT | $0.0519 39.14% 350M
|
Health Technology
XPON | $2.63 36.27% 8.4M
|
ALRN | $5.53 30.12% 250K
|
Health Technology
VTNR S | $1.26 28.68% 9.1M
|
Industrial Services
HOLO | $2.86 27.68% 28M
|
Your saved searches
Save your searches and get alerts when important news are released.